PRMT7 and chronic obstructive pulmonary disease: Therefore, the therapeutic application of bindarit or other PRMT7-targeting strategies in MI should be approached cautiously, especially in patients with comorbidities such as chronic obstructive pulmonary disease, where PRMT7 activation may have pro-inflammatory consequences.